International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 08 Issue: 12 | Dec - 2024 SJIF Rating: 8.448 ISSN: 2582-3930

PHARMACEUTICAL INSPECTION SYSTEM

AISHWARYA LAKSHMI M , KAVIPRIYA S , LAVANYA K , SRI SWETHA B A

Department of Artificial Intelligence and Machine Learning
Sri Shakthi Institute of Engineering and Technology, Coimbatore, India

ABSTRACT

Pharmaceutical quality assurance is a critical aspect of the healthcare industry, requiring exceptional precision and efficiency to ensure the safety, efficacy, and compliance of pharmaceutical products. The increasing complexity of manufacturing processes and stringent regulatory standards pose significant challenges to traditional inspection methods, which rely heavily on manual labor. These methods are not only time-consuming but also prone to human error, which can compromise product quality and safety. To address these challenges, this project introduces a revolutionary system for pharmaceutical inspection powered by YOLOv11, the latest advancement in object detection algorithms. YOLOv11 (You Only Look Once, Version 11) is renowned for its unparalleled accuracy and real-time processing capabilities. This system automates critical quality assurance tasks, including the identification of pharmaceutical products, detection of physical defects, verification of labeling accuracy, and identification of counterfeit medicines. The proposed system integrates advanced image preprocessing techniques with YOLOv11's state-of-the-art feature extraction and detection capabilities. By leveraging deep learning, the system efficiently identifies even the smallest inconsistencies. The application of YOLOv11 in pharmaceutical inspection offers a smarter, faster, and more reliable alternative to traditional methods. Its innovative approach to object detection not only streamlines operations but also sets new benchmarks for accuracy and compliance in quality assurance. This project paves the way for AI-driven inspection workflows, addressing critical industry challenges and ensuring the highest standards of product safety and efficacy.

Keywords—YOLOv11, pharmaceutical inspection, object detection, quality assurance, counterfeit detection.

INTRODUCTION

Quality control is a cornerstone of pharmaceutical manufacturing, where the slightest defect can have significant consequences for patient safety and company reputation. Tablets, being one of the most commonly used drug delivery forms, must adhere to strict quality parameters. Any visual defect, such as a crack, discoloration, or black spots, can indicate underlying issues like poor manufacturing practices, contamination, or material inconsistencies. These defects may affect the tablet's stability, shelf life, and dosage accuracy. Regulatory authorities, such as the FDA and EMA, mandate rigorous quality control measures to eliminate defective products before reaching consumers.

Despite the importance of quality control, many pharmaceutical companies continue to rely on manual inspection methods. This involves human operators visually examining tablets for defects, a process that is not only slow but also prone to human errors. Factors such as fatigue, inconsistent lighting, and subjectivity can lead to missed defects or false positives, resulting in wasted resources or compromised product quality. Additionally, as production scales increase, manual inspection becomes increasingly infeasible due to the sheer volume of tablets requiring inspection.

The advent of artificial intelligence (AI) has introduced new possibilities for automating quality control processes. Deep learning models, particularly in computer vision, have demonstrated remarkable accuracy in tasks like object detection and classification. AI systems can analyze thousands of images in seconds, identifying defects with a level of consistency that surpasses human capabilities. By integrating AI into quality control workflows, companies can achieve greater efficiency, reduce costs, and ensure consistent product quality.

YOLO (You Only Look Once) is a family of object detection algorithms known for their speed and accuracy. YOLOv11, the latest iteration, builds upon its predecessors by incorporating advanced feature extraction techniques, improved bounding box regression, and optimized computational efficiency. Its single-stage architecture processes images in a single forward pass, making it ideal for real-time applications. For this project, YOLOv11 is employed to detect and classify defects in tablets, demonstrating its adaptability to the pharmaceutical domain.

LITERATURE REVIEW

Zero Defect Manufacturing Strategies

Psarommatis et al. surveyed studies published from 1987 to the present on defect elimination in factory production lines - zero defect manufacturing [1]. They pointed out four zero defect manufacturing (ZDM) strategies: detection, repair, prediction, and prevention. ZDM is about reducing faults in the product, part of the product, and the production energy consumption, among several different indicators. Detection is the most used in the above strategies, and the product quality inspection takes place after the product's manufacturing is completed.

Real-Time Defect Detection using yolo

Thi-Thu-Huyen Vu/ Procedia Computer Science 00 (2022) 000–000 3 Li et al. presented a method to detect the Steel strip surface defects in real-time based on the YOLO algorithm [3]. In the approach, they described a method to improve the YOLO network and made it all convolutional. Their method provided an end-to-end solution for detecting the surface defects of steel strips. The network achieved a detection rate of 99% at a speed of 83 FPS. Besides, the method could also predict the location and the size information of defect regions. To improve the YOLO network, they constructed all convolutional in YOLO with 27 convolutional layers. The first 25 layers are used to extract information about surface defect features on the steel strip, and the last two layers are used to predict the category of defects and their bounding boxes. Machine Learning for Defect Prediction

Modified YOLO Network for Defect Detection

Xu et al. presented an approach to modifying the YOLO network to improve metal surface defect detection [25]. The approach generated a new scale feature layer to extract more features of minor defects from the metal surface. To do that, they combined the features of the 11th layer in the Darknet-53 with the in-depth features of the neural network. Consequently, the K-Means++ algorithm was used to decrease the sensitivity of the initial cluster. Their study reached an average result of 75.1% and the processing time was about 83 FPS.

PROPOSED SYSTEM

The proposed pharmaceutical inspection system is designed to automate the detection and classification of defects in tablets during manufacturing, significantly enhancing the quality control process.

Key Features of the Proposed System :

- Automation of Defect Detection

  The primary objective is to replace the traditional manual inspection process, which is time consuming, labor-intensive, and prone to human error. By leveraging advanced machine learning techniques and object detection models like YOLOv11, the system ensures:

  - Consistency: Automated inspection provides uniform evaluation criteria, eliminating subjective biases inherent in manual inspections.
  - Efficiency: High-speed processing allows real-time defect detection, enabling rapid identification and segregation of defective tablets.
  - Scalability: The system can handle large-scale production lines, making it suitable for pharmaceutical manufacturing environments with high output rates.

- Categorization of Tablet Defects

  The system categorizes tablets into three distinct classes:

  - Normal Tablets: Tablets that meet all quality standards without any visible defects. These tablets are deemed fit for packaging and distribution.
  - Black-Spotted Tablets: Tablets with visible spots or discolorations caused by impurities, improper mixing of ingredients, or equipment contamination. These defects are critical as they may indicate contamination or compromised safety.
  - Cracked Tablets: Tablets with physical damage, such as cracks, chips, or fractures. Such defects may result from issues in the compression stage or improper handling during production.

  By classifying defects, the system provides actionable insights to manufacturing teams for targeted corrective actions.

- Ensuring High Precision and Recall

  The system is designed to achieve high precision and recall, which are crucial metrics in quality control:

  - Precision: Ensures that the system identifies true defects with minimal false positives. Helps avoid unnecessary wastage of good tablets that are incorrectly classified as defective.
  - Recall: Ensures that all defective tablets are identified and segregated, reducing the risk of faulty products reaching consumers. A high recall rate is critical in the pharmaceutical industry, where defective products can have severe consequences.

  By balancing precision and recall, the system provides reliable defect detection while maintaining the integrity of quality control.

- Minimizing False Positives

  One of the critical objectives of the proposed system is to minimize false positives, where good tablets are incorrectly flagged as defective. This reduces unnecessary wastage and maximizes production efficiency, ultimately leading to cost savings.

- Improving Consumer Trust

  By ensuring that only defect-free tablets reach the market, the system enhances product quality, safety, and reliability. This builds trust among consumers and regulatory bodies, reinforcing the manufacturer’s commitment to excellence. The proposed system aims to revolutionize tablet inspection in pharmaceutical manufacturing by automating defect detection, ensuring high accuracy, and providing actionable insights for continuous improvement. This contributes

International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 08 Issue: 12 | Dec - 2024 SJIF Rating: 8.448 ISSN: 2582-3930

to safer products, streamlined operations, and enhanced consumer confidence.

METHODOLOGY

The proposed system leverages YOLOv11 (You Only Look Once, Version 11) for real-time, automated defect detection in tablets. It utilizes advanced object detection and classification algorithms to address the limitations of the existing system.

1. Automated Defect Detection:

- The system uses a pre-trained YOLOv11 model fine-tuned with a dataset of annotated tablet images.
- It identifies and categorizes defects into three classes:
  - Normal Tablets: Tablets meeting quality standards.
  - Black-Spotted Tablets: Tablets with visible discoloration or spots.
  - Cracked Tablets: Tablets with structural defects such as cracks or chips.

2. Real-Time Processing:

- The system processes images in real time, ensuring that it can handle the speed of high-volume production lines without delays.
- This minimizes inspection bottlenecks and improves operational efficiency.

3. High Precision and Recall:

- By leveraging YOLOv11's state-of- the-art object detection capabilities, the system achieves high precision (minimizing false positives) and high recall (maximizing defect detection).
- This ensures reliable identification of defective tablets while reducing wastage.

4. Dataset Preparation:

- The system is trained on a diverse dataset of tablet images annotated with defect classes.
- Data augmentation techniques, such as rotation, flipping, and scaling, are used to improve model robustness.

5. Integration with Production Lines:

- High-resolution cameras capture images of tablets as they move along the production line.
- The YOLOv11 model analyzes these images and classifies the tablets in real time.

6. Feedback Loop for Continuous Improvement:

- The system records defect data, enabling manufacturers to identify patterns and trends in production issues.
- Insights from the system are used to fine-tune the production process, reducing defect rates over time.

7. Scalability and Adaptability:

- The system can scale to accommodate increasing production volumes.
- It is adaptable to inspect tablets of different shapes, sizes, and formulations.

EXPERIMENTAL RESULT



CONCLUSION

Pharmaceutical Inspection System for Tablet Quality Analysis successfully demonstrates the feasibility and effectiveness of automating tablet defect detection using the YOLOv11 model. By leveraging advanced object detection techniques, the proposed system addresses critical challenges in pharmaceutical manufacturing, including inconsistent manual inspections and scalability issues. The implementation of this system not only enhances the quality assurance process but also sets the stage for future advancements in automated inspection technologies. While the current model delivers promising results, challenges like dataset imbalance and the need for real- world validation highlight the scope for continuous improvement. In conclusion, this project demonstrates a significant step forward in integrating AI-powered solutions into pharmaceutical manufacturing. By providing a robust and scalable solution for tablet inspection, it has the potential to revolutionize quality control practices, ensuring better product reliability and consumer safety.

REFERENCES

1. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel P. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing. Clin Pharmacol Therap. 2018;105(4):954 61.
2. Cabitza F, Rasoini R, Gensini G. Unintended Consequences of Machine Learning in Medicine. JAMA. 2017;318(6):517.
3. Nayak V, Khan M, Shukla B, Chaturvedi P. Artificial intelligence in clinical research. Int J Clin Trials. 2016;3(4):187-93.
4. Hoodbhoy Z, Hasan B, Siddiqui K. Does artificial intelligence have any role in healthcare in low resource settings? J Med Art Intel. 2019;2:13- 13.
5. Healthcare in 2065. 2021. Available at: https://www2.deloitte.com/content/da m/Deloitte/sg/D ocuments/risk/sg-risk-healthcare 2065-noexp.pdf. Accessed on 24 January 2021.
6. Danysz K, Cicirello S, Mingle E, Assuncao B, Tetarenko N, Mockute R, et al. Artificial Intelligence and the Future of the Drug Safety Professional. Drug Safety. 2018;42(4):491-7.
7. Mockute R, Desai S, Perera S, Assuncao B, Danysz K, Tetarenko N, et al. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation. Pharm Med. 2019;33(2):109-20.
8. Chan H, Hadjiiski L, Samala R. Computer-aided diagnosis in the era of

deep learning. Med Physics. 2020;47(5).
9. Frey C, Osborne M. The future of employment: How susceptible are jobs to computerization? 2021. Available at: https://www.oxfordmartin.ox.ac. uk/publications/the-future-of- employment/. Accessed on 24 January 2021.
10. Marr B. Instead of Destroying Jobs Artificial Intelligence (AI) Is Creating New Jobs In 4 Out Of 5 Companies. Forbes. https://www.forbes.com/sites/bernard marr/2017/10/1 2021. Available at: 2/instead-of-destroying-jobs artificial-intelligence-ai is-creating-new-jobs-in- 4-out-of-5-companies/. Accessed on 24 January 2021.
11. WHO Policy Perspectives on Medicines. Looking at the Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization. Available at: http://apps.who.int/medic inedo cs/pdf/s6164 e/s6164 e.pdf. Accessed on 15 December 2020.
12. Basile A, Yahi A, Tatonetti N. Artificial Intelligence for Drug Toxicity and Safety. Trends Pharmacol Sci. 2019;40(9):624-35.
13. Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. 2015;54:202-12.
14. Caster O, Dietrich J, Kürzinger M, Lerch M, Maskell S, Norén G et al. Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. Drug Safety. 2018;41(12):1355-69.
15. Yang C, Yang H, Jiang L. Post marketing Drug Safety Surveillance Using Publicly Available Health Consumer-Contributed Content in Social Media. 2014;5(1):1-21.
16. Wang X, Hripcsak G, Markatou M, Friedman C. Active Computerized Pharmacovigilance Using Natural Language Processing, Statistics, and Electronic Health Records: A Feasibility Study. J Am Med Informat Assoc. 2009;16(3):328-37.
17. Luo Y, Thompson W, Herr T, Zeng Z, Berendsen M, Jonnalagadda S et al. Natural Language Processing for EHR- Based Pharmacovigilance: A Structured Review. Drug Safety. 2017;40(11):1075-89.
18. UMC WHO. Available at: https://www.who umc.org/about- us/who-we-are/. Accessed on 11 October 2018.
19. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24:773-80.
20. Duch W, Swaminathan K, Meller J. Artificial intelligence approaches for rational drug design and discovery. Curr Pharm Des. 2007;13(14):1497- 508.
21. Blasiak A, Khong J, Kee T. CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence. SLAS Technol. 2020;25(2):95-105.
22. Mishra V. Artificial intelligence: the beginning of a new era in pharmacy profession. Asian J Pharm. 2018;12(2).
23. Sellwood MA. Artificial intelligence in drug discovery. Future Sci. 2018; 2025-8.
24. Álvarez-Machancoses Ó, Fernández- Martínez JL. Using artificial intelligence methods to speed up drug discovery. Expert Opin Drug Disc. 2019;14:769-77.
25. Fleming N. How artificial intelligence is changing drug discovery. Nature. 2018;557:55.
26. Harrer S. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40:577 91.
27. Hay M. Clinical development success rates for investigational drugs. Nature Biotechnol. 2014;32:40 51.